Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EMBL Choose ambr Micro Bioreactor System for Insect Cell Culture

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Enabling rapid production of human multi-protein complexes using baculovirus.

TAP Biosystems has announced that its advanced micro bioreactor system (ambr™) is in use at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, one of the world’s leading structural biology research institutes, for rapid small scale parallel expression of human multi-protein complexes using baculovirus.

The ambr micro bioreactor system at EMBL, which was funded by the French Investissement d'Avenir Initiative is being used by EMBL scientists in the Eukaryotic Expression Facility (EEF) for culturing insect cells containing baculovirus expression systems to produce differently engineered human multi-protein complexes for crystallography studies.

These protein complexes are being assessed to determine the architecture of protein cascades and pathways that lead to human disease states.

Researchers at EMBL believe that determining these pathways will ultimately reveal pivotal points where protein complexes could be of interest in drug discovery, or as a novel class of therapeutics.

Dr Imre Berger, Group Leader, in the EEF explained: “We use baculovirus because it ensures correct expression and solubility of multi-protein complexes, as well as provides sufficient protein for crystallization. We need to study large numbers of protein complex variants and had been using shake flasks to do this.  However, this type of manual culture method is not practical for us as it is time consuming and almost impossible to evaluate many variants in parallel. So we decided last year to automate the process and when we saw the ambr system we realized that the new ambr workstation with active cooling could help to streamline multi-protein expression and accelerate our research.”

Berger added: “Our difficulty is that using baculovirus and insect cells is not like working with CHO [Chinese Hamster Ovary] cells. The cells require lower growth temperatures, and you have to add baculovirus at a specific time point for successful infection. The new ambr version overcomes these issues, allowing us to grow our insect cells at 27ºC and carry out automated virus additions. TAP’s application specialists have worked with us, showing us how to use the software to monitor cell growth during culture, and set up optimal automated infection timing. We are very happy with using ambr for baculovirus expression in insect cells. Miniaturizing baculovirus expression with the ambr is now an integral part of the ComplexINC research programme and it will have a significant impact on the pace of our work.”

Dr Barney Zoro, ambr Product Manager at TAP Biosystems concluded: "We’re delighted that this world leading research institute has chosen ambr and has, for the first time, successfully proven insect cell growth and protein expression in ambr. Their research demonstrates that ambr can facilitate small scale rapid parallel production of large sets of multi-protein complexes with baculovirus, and may potentially help uncover new targets for use in future drug discovery programmes, or even a novel class of protein therapeutics.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck and TAP Biosystems Finalists for “Best Collaboration Award”
Recognizing ambr250 as a breakthrough technology for process development.
Wednesday, October 08, 2014
TAP and Gallus Co-host Free Webinar
Explaining the benefits of using ambr15 microbioreactors for DoE.
Wednesday, October 01, 2014
New Webinars Explore Feed Strategy Challenges Using Mini Bioreactors
Detailing how to achieve consistent feeding regimes for reproducible scale-up.
Thursday, September 25, 2014
New Webinar on Mimicking Perfusion Culture Using Micro Bioreactors
Presents validation data for improving media screening and process optimization.
Friday, February 14, 2014
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!